A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CIMPASI-1
  • Sponsors UCB
  • Most Recent Events

    • 25 Jul 2017 According to an UCB media release, based on the data from CIMPASI-1 CIMPASI-2 and CIMPACT studies, an sBLA to the US FDA and a regulatory filing with the EMA has been submitted to expand the approved indications for certolizumab pegol to include treatment of adult patients with moderate-to-severe chronic plaque psoriasis.An additional submission to expand the use of CIMZIA in this patient population is also planned with Health Canada.
    • 04 Mar 2017 According to an UCB media relesase, 16-week results has been presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD).
    • 04 Mar 2017 Results published in an UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top